ALS has proven stubbornly resistant to medicinal breakthroughs, with just one new drug securing U.S. approval in the last 22 years. Cytokinetics (CYTK) hopes to change that with the readout of a large clinical trial within the next two weeks.

Success will require beating long odds. Here are seven things you need to know about Cytokinetics and its experimental ALS drug tirasemtiv before the clinical trial results are announced.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • David Salinas. I am not sure where your comment comes from. The basic DP costs about $200/mo. I don’t sell it and don’t control the price. You can buy it from Simplesa or buy the substances separately online. They are all on Amazon.

  • ALS patients respond to the DP which suppresses muscle symptoms and can be cured by a combination of antibiotics b/c it is caused by Borrelia and co-infections. So many dead, so much money wasted.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy